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CarotidAbstract Background: Data from epidemiological studies and randomized clinical trials strongly
suggest that obstructive sleep apnea (OSA) is associated with elevated risk of cardiovascular events.
Although OSA and cardiovascular diseases share many risk factors, studies have demonstrated that
OSA is an independent risk factor of arterial hypertension and atherosclerosis.
Objective: To determine the impact of treatment with continuous positive airway pressure
(CPAP) on carotid artery intima-media thickness (CIMT) in patients with OSA.
Methods: 40 newly diagnosed OSA patients were assigned into two groups. Conservative treat-
ment group (CT, n= 20) which refused CPAP treatment, and CPAP group (CPAP, n= 20) which
received CPAP treatment. CIMT was determined at baseline and after 6 months.
Results: Mean follow-up time was 6.1 ± 2.1 months. At baseline, all measurements were similar
in both groups and did not change significantly in CT group after 6 months. In contrast, a signif-
icant change occurred in CIMT in CPAP group (8 (20) vs. 115 (10) lm, p= 0.03) from baseline.
Conclusion: CPAP significantly reduced CIMT in OSA patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
OSA is a common sleep related breathing disorder character-
ized by repetitive upper airway collapse during sleep resulting
in intermittent hypoxia, sleep fragmentation and sympatheticover-activity. The condition affects all age groups and is preva-
lent across different populations globally [1].
Although OSA and cardiovascular diseases share many risk
factors, studies have demonstrated that OSA is an independent
risk factor of arterial hypertension and atherosclerosis [2].
The mechanisms of this relationship are incompletely under-
stood. However, the evidence suggests that intermittent
hypoxia and the arousal response are likely the main patho-
physiologic factors associated with oscillation of systemic and
pulmonary arterial blood pressures, heart rate, and cardiac
function. These factors expose the heart and circulation to a
766 M. Amincascade of noxious stimuli that, over time, may initiate or con-
tribute to the progression of most cardiovascular disorders [3].
In everyday practice, attention is usually paid to atheroscle-
rotic plaques in the vessels, typical of advanced atherosclerosis
with organ dysfunction. However, atherosclerosis is a chronic,
progressive, pathological process with a long asymptomatic
subclinical phase [4]. In recent years, CIMT has been well
accepted as a non-invasive tool which may predict the likeli-
hood of acute coronary events and stroke in asymptomatic
healthy subjects [4,5]. Therefore, assessment of CIMT as an
early predictor for atherosclerotic changes seems to be a much
better approach.
Ultrasonography—a noninvasive, quick, and reproducible
technique—can be used to evaluate the atherosclerotic process
at an early stage. CIMT correlates well with anatomic mea-
surements and is a marker of both structural vascular damages
and in prediction of the cardiovascular risk in asymptomatic
healthy subjects [2]. Epidemiological and interventional studies
frequently use CIMT as a surrogate marker for subclinical or
early atherosclerosis [3].
CPAP is the treatment of choice for patients with symp-
tomatic OSA, as it has been shown to improve daytime sleepi-
ness, alertness and quality of life and to decrease blood
pressure [6–8]. Whether CPAP treatment is effective in coun-
teracting the autonomic imbalance and increased arterial stiff-
ness in patients with OSA remains a matter of debate [9].
Aim of the present study
The aim of the present study is to evaluate the effect of CPAP
vs. conservative treatment on CIMT over a period of 6 months
in OSA patients.
Patients and methods
The present study was conducted as prospective observational
study for the treatment effects on CIMT in 40 newly diagnosed
OSA patients. OSA was defined by an overnight portable sleep
study showing apnea–hypopnea index (AHI) P5/h of sleep
plus excessive daytime sleepiness or two of the following symp-
toms: choking or gasping during sleep, recurrent awakenings
from sleep, unrefreshed sleep, daytime fatigue, and impaired
concentration [10,11].
The exclusion criteria included patients known to have
coronary artery disease or receiving lipid-lowering agents for
dyslipidemia or previously diagnosed to have OSA.
Sleep assessment
Overnight diagnostic portable sleep study (Embletta gold, level
III) was performed for every subject recording chest and
abdominal wall movement by inductance plethysmography,
airflow measured by a nasal pressure transducer [11,12]. Apnea
was defined as cessation of airflow – or its reduction by 90% –
for >10 s and hypopnea as a reduction of airflow of P30%
for >10 s plus an oxygen desaturation of >3%. Following
confirmation of OSA, all patients were arranged to undergo
overnight autoCPAP titration. All patients were given a basic
CPAP education program by a respiratory technician supple-
mented by education booklet [11,12]. The technician would
fit a comfortable CPAP mask from a wide range of selectionfor every patient, who was then given a short trial of CPAP
therapy with the Autoset (ResMed, Sydney, Australia) CPAP
device for 3 days. Following the overnight autoCPAP titration
study, each patient was interviewed and invited to participate
in the serial CIMT study.
Conservative treatment group (CT, n = 20)
After confirmation of significant OSA and completion of over-
night autoCPAP titration, 20 patients who were not keen to
start CPAP yet were encouraged to (a) avoid sleep deprivation
by having sufficient hours of sleep every night; (b) sleep in lat-
eral positions; (c) avoid sedatives and alcohol consumption;
and (d) lose weight by exercise and diet [13]. This group was
labeled as conservative treatment group (CT).
CPAP group (CPAP, n = 20)
In addition to the usual advice as given to CT group, 20
patients had agreed to commence CPAP treatment for >5 h/
night after completing an overnight autoCPAP titration. They
were subsequently prescribed CPAP device with a time counter
recording machine run time. The CPAP pressure for each
patient was set at the minimum pressure needed to abolish
snoring, obstructive respiratory events, and airflow limitation
for 95% of the night as determined by the overnight AutoSet
CPAP titration study [11,12]. This group was labeled as CPAP
group (CPAP).
Carotid artery intima-media thickness (CIMT)
CIMT was measured at baseline and 6 months for patients in
both groups. The patients were followed up at the Respiratory
clinic monthly whereas objective CPAP usage was measured
from the time counter for CPAP group. CIMT was assessed
by B-mode ultrasound scanning with compound and harmonic
imaging to reduce the near field artifacts [14]. Bilateral CIMT
measurements were obtained at the distal 10 mm of common
carotid artery [15,16]. The CIMT was defined as the distance
between the leading edge of the luminal echo to that of the
media/adventitia echo (only the intima ‘‘echogenic layer”
and the media ‘‘echo-poor layer” are included), and analyzed
with a computerized edge-detection system. Carotid artery
IMT was assessed by B-mode ultrasound scanning with a 12-
MHz linear phase array transducer. Carotid IMT measure-
ment by ultrasound was done using a semiautomated border
detection program with validated accuracy. Three end-
diastolic frames were selected, digitized, and analyzed for the
mean IMT, and the average reading from these 3 frames was
calculated for both right and left carotid arteries. The sole car-
otid scan operator was blinded to the clinical treatment status
of the studied subjects and was not involved in the clinical
assessment. Blood pressure (BP) was measured in the right
arm after at least 15 min of rest using a standard sphygmo-
manometer before PSG and at clinic visits at 6 months.
Statistical analysis
The sample size was estimated by the Power Analysis
and Sample Size for Windows software (PASS 2000, NCSS,
Table 1 Comparisons between CT and CPAP groups regarding different variables.
Characteristics CT group (n= 20) CPAP group (n= 20) p Value
Age 49 (12) 51 (11) 0.21
Sex, male/female 17/3 15/5 0.50
Smoking: yes/no 8/12 7/13 0.51
HTN: yes/no 14/6 12/8 0.31
DM: yes/no 7/13 8/12 0.27
Systolic blood pressure (mmHg) 142.3 (5.1) 139.5 (6.1) 0.38
Diastolic blood pressure (mmHg) 82.5 (3.2) 85.8 (2.7) 0.75
BMI (kg/m2) 32.2 (0.3) 33.7 (1.2) 0.47
Neck circumference (cm) 37 (9.1) 39 (2.8) 0.09
Waist circumference (cm) 94.6 (2.1) 97.4 (1.7) 0.62
Hip circumference (cm) 105.1 (1.9) 101.3 (1.2) 0.41
Fasting plasma glucose (mg/dl) 95 (10) 102 (3) 0.67
Total blood cholesterol (mg/dl) 235 (31) 241 (42) 0.34
Blood triglyceride (mg/dl) 167 (61) 173 (49) 0.51
CIMT (lm) 693 (30) 702 (30) 0.47
Data expressed as mean (SE); CT, conservative treatment; CPAP, continuous positive airway pressure; HTN, hypertension; DM, diabetes
mellitus; BMI, body mass index; lm, micrometer; p value > 0.05 is statistically insignificant.







AHI 44 (13) 51 (17) 0.37
SpO2 < 90% 32 (19) 36 (21) 0.61
Lowest SpO2 77 (11) 72 (13) 0.32
ESS 14 (3) 13 (4) 0.27
ODI 55 (17) 61 (19) 0.41
Data expressed as mean (SE); CT, conservative treatment; CPAP,
continuous positive airway pressure; AHI, apnea–hypopnea index;
SpO2 < 90%, pulse oximetry <90% during sleep time as per-
centage of total sleep time; ESS, Epworth sleepiness scale (0–24),
ODI, oxygen desaturation events; p value > 0.05 is statistically not
significant.
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CIMT. Data are expressed as mean ± standard error (SE)
unless stated otherwise. A p-value of <0.05 is considered sta-
tistically significant.
Results
40 newly confirmed OSA patients were collected. They had
met the study criteria to participate in the serial CIMT study
after completing PSG and an overnight autoCPAP titration.
However, 20 eligible patients refused CPAP treatment and pre-
ferred conservative management (CT group) and 20 patients
had agreed to commence CPAP treatment (CPAP group) in
addition to the usual advice given to CT group.
Among the 40 studied patients who had completed study,
the demographics and CIMT between the two groups were
similar (Table 1).
Among the 40 studied patients who had completed study,
the severity of OSA between the two groups was similar
(Table 2).Comparison of parameter changes between CT and CPAP
The serial mean CIMT at baseline, and 6 months were 693 (30)
and 701 (20) lm for the CT group (Table 3) whereas the serial
mean CIMT for the CPAP group were 702 (30), and 587 (30)
lm respectively, p= 0.03 (Table 3).
Discussion
In a group of 40 symptomatic patients newly diagnosed with
severe OSAS, this prospective observational study has shown
that CPAP treatment (CPAP group, n= 20) resulted in a sig-
nificant reduction in carotid artery IMT compared to those
who had preferred conservative treatment (CT group,
n= 20) over a study period of 6 months.
Data from epidemiological studies and randomized clinical
trials strongly suggest that OSA is associated with elevated risk
of cardiovascular events [17]. Although OSA and cardiovascu-
lar diseases share many risk factors, studies have demonstrated
that OSA is an independent risk factor of arterial hypertension
and atherosclerosis [3,18].
There are several proposed published mechanisms that
linked OSA and stroke. Sahlin et al. stated that patients with
stroke and OSA have an increased risk of early death over
10 years [19], whereas sleep apnea is significantly associated
with increased risk of stroke among patients with coronary
artery disease over a follow-up period of 10 years [20]. Kohler
and his colleges assessed cardiovascular risk of OSA and
CPAP effect in males. After 4 weeks of therapeutic CPAP, a
significant reduction was seen in sympathetic activity (evalu-
ated by urine normetanephrine excretion), arterial stiffness
(evaluated by augmentation index), mean ambulatory arterial
blood pressure and significantly improved baroreflex sensitiv-
ity. They suggested that treatment of OSA with CPAP may
lower cardiovascular risk [9]. Likewise data from the Sleep
Heart Health Study (SHHS) have shown that modest to severe
levels of OSA are associated with an approximately threefold
increased risk of ischemic stroke in community-dwelling men
[21]. In an observational sleep clinic study, Yaggi et al. [22]
Table 3 Comparisons between CT and CPAP regarding mean CIMT at baseline and after 6 months (lm).
CT group (n= 20) CPAP group (n= 20)
Baseline 6 months Change p value Baseline 6 months Change p value
693 (30) 701 (20) 8 (20) 0.45 702 (30) 587 (30) 115 (10) 0.03
Data expressed as mean (SE); p value  0.05 is statistically significant.
768 M. Aminhave shown that OSA significantly increases the risk of stroke
or death from any cause and the increase is independent of
other known risk factors.
Gami et al. stated that there is a strong association between
OSA and AF [23]. Many mechanisms have been suggested for
this issue. OSA may accelerate atherosclerosis through the
effect of hypertension and other mechanisms such as insulin
resistance, diabetes, and dyslipidemia. In addition, OSA can
induce direct proatherogenic effects through the mechanisms
of systemic inflammation, oxidative stress, vascular smooth
cell activation, increased adhesion molecule expression, mono-
cyte/lymphocyte activation, increased lipid loading in macro-
phages, lipid peroxidation, and endothelial dysfunction [24].
Platelet activation [12] and silent brain infarction were also
more common in patients with moderate to severe OSA than
in controls [25]. Snoring-induced vibrational injury may lead
to carotid atherosclerosis [26].
Recently, evaluation of CIMT has been well accepted as a
non-invasive tool which may predict the likelihood of acute
coronary events and stroke in asymptomatic healthy subjects
[4]. CIMT has been applied by several research groups to study
different OSA populations.
Data from many studies have suggested that OSA may lead
to early atherosclerosis, as reflected by an increase in CIMT
and occurrence of plaques, in the absence of any significant
comorbidity [27–29]. OSA related hypoxia and systemic
inflammation might be associated with progression of
atherosclerosis and increased risk of cardiovascular morbidity
[29]. Baguet and colleges suggested that severity of oxygen
desaturation and blood pressure status were the best predictors
for carotid wall hypertrophy whereas plaque occurrence with-
out known cardiovascular disease was also related to the
amount of oxygen desaturation regardless of their blood pres-
sure status [28]. Another study by Monneret et al. demon-
strated a relationship between lipid peroxidation, carotid
artery IMT, and intermittent hypoxia in non-obese OSA
patients [30] whereas in patients with minimally symptomatic
OSA, diverse properties of endothelial function are impaired
and arterial stiffness is increased [31].
In the present study, there were significant differences when
comparing the changes in CIMT at 6 months [8 (20) vs. 115
(10) lm] from baseline between CT and CPAP groups. Many
published studies suggested this CPAP beneficial effect
[32,9,33,34,3]. Dragger et al. randomly assigned 24 patients
with severe OSA who were free of comorbidities to receive
no treatment (control, n= 12) or CPAP treatment (n= 12)
for 4 months. They found a significant reduction in CIMT in
CPAP group [32]. Hui and colleges examined a long-term
effect of CPAP on CIMT in OSA patients. They observed a
significant reduction in CIMT in patients with reasonable
CPAP compliance compared to patients who refused this
modality of treatment. The beneficial effect of CPAP occurred
mostly in the first 6 months and was sustained at 12 months[33]. Agha and Habib assessed CPAP effect on CIMT in
OSA patients. They reported a highly significant difference
(p< 0.01) in CIMT between OSA patients and control group
(10 obese non-OSA individuals). They observed a highly sig-
nificant reduction (p< 0.01) in CIMT after 6 months of
CPAP usage [34].
Although we did not find any significant correlation
between objective CPAP usage and carotid IMT in this study,
variability in the individual response may be related to the
severity of OSA (AHI, hypoxemia) and CPAP compliance.
In contrast to the present study, Sharma and colleges pub-
lished a double-blind, placebo-controlled trial. They randomly
assigned OSA patients to undergo 3 months of therapeutic
CPAP followed by 3 months of sham CPAP, or vice versa,
with a washout period of 1 month in between. Results revealed
no significant reduction in CIMT with CPAP (n= 43) vs.
sham CPAP (n= 43). However, a subgroup analysis among
those (n= 51) with CPAP usage at least 5 h/night showed sig-
nificant reduction in CIMT (34 vs. 14 lm, p< 0.05) when
comparing CPAP vs. sham CPAP treatment over 3 months
[35].
Several limitations to the present study include the follow-
ing. First, the study had a relatively small sample size. Second,
it was not a randomized clinical trial as it would not be ethical
to withhold CPAP treatment for symptomatic patients. Third,
we did not study any inflammatory markers in blood, OSA
severity and its relation to CPAP effect on CIMT. Lastly only
baseline data of many variables like glucose and lipids were
available and we did not have serial data to assess the treat-
ment effects.
Conclusion
In summary, CPAP treatment resulted in a significant reduc-
tion in CIMT over a study period of 6 months, whereas no sig-
nificant change was noted among those who refused this
treatment modality. Newly diagnosed OSA patients should
be encouraged to commence CPAP not just to relieve daytime
sleepiness but also due to its cardio-protective effects. Further
studies are warranted to assess these findings.
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